Milestone Pharmaceuticals (NASDAQ:MIST) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.
Risk & Volatility
Milestone Pharmaceuticals has a beta of 4.2, suggesting that its stock price is 320% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500.
Valuation & Earnings
This table compares Milestone Pharmaceuticals and Albireo Pharma's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Milestone Pharmaceuticals | N/A | N/A | $-55,230,000.00 | ($3.50) | -1.54 |
| Albireo Pharma | $9.64 million | 64.22 | $-62,720,000.00 | ($5.04) | -6.43 |
Milestone Pharmaceuticals has higher earnings, but lower revenue than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Milestone Pharmaceuticals and Albireo Pharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Milestone Pharmaceuticals | N/A | -58.89% | -55.37% |
| Albireo Pharma | -751.53% | -71.22% | -42.91% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Milestone Pharmaceuticals and Albireo Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Milestone Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
| Albireo Pharma | 0 | 0 | 8 | 0 | 3.00 |
Milestone Pharmaceuticals presently has a consensus target price of $14.60, indicating a potential upside of 167.89%. Albireo Pharma has a consensus target price of $72.00, indicating a potential upside of 122.57%. Given Milestone Pharmaceuticals' higher possible upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Albireo Pharma.
Insider and Institutional Ownership
51.9% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are held by institutional investors. 4.2% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Albireo Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Milestone Pharmaceuticals beats Albireo Pharma on 7 of the 13 factors compared between the two stocks.
